William Zamboni received his bachelor of science, doctor of pharmacy and doctor of philosophy from the University of Pittsburgh School of Pharmacy in Pittsburgh, Pennsylvania. He completed his oncology residency at the Warren G. Magnuson Clinical Center, National Institutes of Health, in Bethesda, MD and his research fellowship at the Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, in Memphis, Tennessee.
Currently, he is an associate professor in the UNC Eshelman School of Pharmacy and UNC Lineberger Comprehensive Cancer Center. Zamboni’s research program is part of the Division of Pharmacotherapy and Experimental Therapeutics n the UNC Eshelman School of Pharmacy and Molecular Therapeutics in the UNC Lineberger Comprehensive Cancer Center. He is the director of UNC GLP Bioanalytical Facility and the director of the Translational Oncology and Nanoparticle Drug Development Initiative (TOND2I) Lab at the University of North Carolina in Chapel Hill. He is also the codirector of the North Carolina Biomedical Innovation Network (NCBIN) for GLP toxicology and pharmacology studies of small molecule and nanoparticle agents.
Zamboni has been involved in translational studies of anticancer agents for several years. His research interests focus on the application of pharmacokinetic, pharmacodynamic, and pharmacogenetic principles in the optimization of the chemotherapeutic treatment of cancer. Information obtained from preclinical and clinical translational studies can greatly add to the understanding of the pharmacology of anticancer agents; permit individualization of chemotherapeutic treatment based on pharmacokinetic, pharmacodynamic, and pharmacogenetic principles; and allow for the rational design of therapeutic regimens.
A second focus of his research is on the developments of nanosomal and nanoparticle anticancer agents and evaluating the relationship between the disposition f the s agents and the reticuloendothelial system. As part of these studies, he has used microdialysis to evaluate the tumor extracellular fluid disposition of anticancer agents and factors affecting the delivery and removal of anticancer agents. He has also developed methods and technologies to differentiate between the inactive-encapsulate and active-release forms of the drugs and is evaluating potential phenotypic probes from the pharmacokinetic and pharmacodynamic disposition of nanosomal and nanoparticles. The clinical relevance of studies is underscored by the need to treat solid tumors with anticancer agents that have a high tumor delivery of liposomal and nanoparticle agents and generate administration schedules to enhance selective tumor uptake.
Education, Certification and Licensure
Doctor of Philosophy, Clinical Pharmaceutical Scientist Program, Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, 2001 to 2005
Dissertation: “Preclinical and Clinical Pharmacologic Studies of 9-Nitrocamptothecin and Its 9-Aminocamptothecin Metabolite.”
Research Fellowship, Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN, 1995 to 1997
Oncology Pharmacy Residency, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, 1994 to 1995
Doctor of Pharmacy, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, 1992 to 1994
Bachelor of Science in Pharmacy, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, 1988 to 1992